Adimmune Corporation (4142.TW)
TWD 18.85
(-3.83%)
TWD 18.85
(-3.83%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 685.12 Million TWD | 215.24% |
| 2022 | -594.5 Million TWD | 55.34% |
| 2021 | -1.33 Billion TWD | 51.87% |
| 2020 | -2.76 Billion TWD | -286.93% |
| 2019 | 1.47 Billion TWD | -48.19% |
| 2018 | 2.85 Billion TWD | 59.61% |
| 2017 | 1.78 Billion TWD | -1.61% |
| 2016 | 1.81 Billion TWD | 176.6% |
| 2015 | 657.47 Million TWD | 284.28% |
| 2014 | 171.09 Million TWD | -88.86% |
| 2013 | 1.53 Billion TWD | 49.47% |
| 2012 | 1.02 Billion TWD | 4.41% |
| 2011 | 984.46 Million TWD | 206.45% |
| 2010 | 321.24 Million TWD | -17.09% |
| 2009 | 387.44 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 453.89 Million TWD | 173.93% |
| 2024 Q1 | 165.69 Million TWD | -75.82% |
| 2023 Q2 | 275.62 Million TWD | 556.42% |
| 2023 Q4 | 685.12 Million TWD | 3.79% |
| 2023 Q1 | -60.38 Million TWD | 89.84% |
| 2023 FY | 685.12 Million TWD | 215.24% |
| 2023 Q3 | 660.08 Million TWD | 139.48% |
| 2022 Q3 | 166.28 Million TWD | 139.55% |
| 2022 FY | -594.5 Million TWD | 55.34% |
| 2022 Q1 | -993.64 Million TWD | 25.36% |
| 2022 Q2 | -420.44 Million TWD | 57.69% |
| 2022 Q4 | -594.5 Million TWD | -457.52% |
| 2021 FY | -1.33 Billion TWD | 51.87% |
| 2021 Q3 | -905.12 Million TWD | 40.68% |
| 2021 Q4 | -1.33 Billion TWD | -47.08% |
| 2021 Q2 | -1.52 Billion TWD | 32.03% |
| 2021 Q1 | -2.24 Billion TWD | 18.84% |
| 2020 Q2 | -898.38 Million TWD | -166.06% |
| 2020 Q3 | -769.46 Million TWD | 14.35% |
| 2020 Q4 | -2.76 Billion TWD | -259.44% |
| 2020 FY | -2.76 Billion TWD | -286.93% |
| 2020 Q1 | -337.65 Million TWD | -122.82% |
| 2019 Q1 | 2.73 Billion TWD | -4.13% |
| 2019 Q2 | 1.01 Billion TWD | -62.85% |
| 2019 Q3 | 1.35 Billion TWD | 33.4% |
| 2019 FY | 1.47 Billion TWD | -48.19% |
| 2019 Q4 | 1.47 Billion TWD | 9.04% |
| 2018 Q4 | 2.85 Billion TWD | 7.62% |
| 2018 FY | 2.85 Billion TWD | 59.61% |
| 2018 Q1 | 2 Billion TWD | 12.31% |
| 2018 Q2 | 2.44 Billion TWD | 21.71% |
| 2018 Q3 | 2.65 Billion TWD | 8.49% |
| 2017 Q2 | 1.77 Billion TWD | 12.43% |
| 2017 Q1 | 1.58 Billion TWD | -12.95% |
| 2017 FY | 1.78 Billion TWD | -1.61% |
| 2017 Q4 | 1.78 Billion TWD | -11.29% |
| 2017 Q3 | 2.01 Billion TWD | 13.31% |
| 2016 FY | 1.81 Billion TWD | 176.6% |
| 2016 Q4 | 1.81 Billion TWD | 35.93% |
| 2016 Q3 | 1.33 Billion TWD | 24.99% |
| 2016 Q2 | 1.07 Billion TWD | 27.61% |
| 2016 Q1 | 838.79 Million TWD | 27.58% |
| 2015 Q2 | 506.83 Million TWD | 173.72% |
| 2015 Q3 | 733.6 Million TWD | 44.74% |
| 2015 FY | 657.47 Million TWD | 284.28% |
| 2015 Q4 | 657.47 Million TWD | -10.38% |
| 2015 Q1 | 185.16 Million TWD | 8.22% |
| 2014 Q1 | 1.43 Billion TWD | -6.55% |
| 2014 FY | 171.09 Million TWD | -88.86% |
| 2014 Q4 | 171.09 Million TWD | 271.92% |
| 2014 Q2 | 1.43 Billion TWD | 0.2% |
| 2014 Q3 | -99.52 Million TWD | -106.92% |
| 2013 Q2 | 1.41 Billion TWD | 21.37% |
| 2013 Q4 | 1.53 Billion TWD | 10.44% |
| 2013 FY | 1.53 Billion TWD | 49.47% |
| 2013 Q1 | 1.16 Billion TWD | 13.28% |
| 2013 Q3 | 1.39 Billion TWD | -1.57% |
| 2012 Q4 | 1.02 Billion TWD | -5.13% |
| 2012 Q3 | 1.08 Billion TWD | 28.84% |
| 2012 Q1 | 1.14 Billion TWD | 16.48% |
| 2012 FY | 1.02 Billion TWD | 4.41% |
| 2012 Q2 | 840.92 Million TWD | -26.66% |
| 2011 Q4 | 984.46 Million TWD | 28.9% |
| 2011 Q2 | 601.65 Million TWD | 0.0% |
| 2011 Q3 | 763.72 Million TWD | 26.94% |
| 2011 FY | 984.46 Million TWD | 206.45% |
| 2010 FY | 321.24 Million TWD | -17.09% |
| 2010 Q4 | 321.24 Million TWD | 0.0% |
| 2009 FY | 387.44 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | -201.21 Million TWD | 440.496% |
| Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | 21.298% |
| Panion & Bf Biotech Inc. | 193.2 Million TWD | -254.607% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 27.079% |
| GenMont Biotech Incorporation | 2.71 Million TWD | -25162.869% |
| Abnova (Taiwan) Corporation | -415.8 Million TWD | 264.77% |
| Tanvex BioPharma, Inc. | 1.35 Billion TWD | 49.288% |
| Polaris Group | -2.41 Billion TWD | 128.323% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 377.821% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | -1158.734% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | -13936.652% |